ALV
0.047
104.3%
WLD
0.014
-51.7%
SRN
0.002
100%
MEL
0.001
-50%
MML
0.034
54.5%
QFE
0.067
-46.4%
C7A
0.003
50%
JNS
0.099
-41.8%
IRX
0.036
38.5%
SFX
0.072
-34.5%
1AI
0.012
33.3%
DRO
1.715
-34%
FRS
0.265
32.5%
CHM
0.002
-33.3%
ROC
0.165
32%
TEM
0.007
-30%
RAS
0.038
31%
ECS
0.005
-28.6%
ECL
4.31
30.6%
USL
0.49
-27.4%
CXU
0.022
29.4%
IFG
0.008
-27.3%
MRD
0.033
26.9%
RNV
0.115
-25.8%
GW1
0.038
26.7%
AI1
0.057
-25%
STM
0.024
26.3%
BIT
0.003
-25%
PMT
0.505
26.3%
KRR
0.012
-25%
BPM
0.17
25.9%
SPX
0.003
-25%
RKB
0.005
25%
ASN
0.079
-24.8%
TGN
0.155
24%
C29
0.019
-24%
GT1
0.037
23.3%
SVY
0.013
-23.5%
A11
0.22
22.2%
NC1
0.1
-23.1%
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Cleo Diagnostics (ASX:COV): Bringing to market a simple blood test

Cleo Diagnostics (ASX:COV) is attempting to bring to market a simple blood test for the accurate and early diagnosis of ovarian cancer based on the novel patented CXCL10 biomarker, which is produced early and at high levels by ovarian cancers but is largely absent in nonmalignant disease. The test aims to distinguish benign from malignant growths in a standard format that will be readily compatible with existing equipment used by diagnostic laboratories worldwide | Investor presentation: https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02774453-3A636747